MedTrace Logo

Evaluation of Oxidative Stress and Inflammation Markers in Temporomandibular Disorders

NCT05985733 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2023-08-14

No results posted yet for this study

Summary

Background: The occurrence of many diseases has been associated with oxidative stress and disruption of antioxidant mechanisms. Temporomandibular Joint(TMJ) Disorders are also thought to develop with the onset of the destructive process in the tissues as a result of this balance being disrupted.

Purpose: This study was designed to compare salivary and serum oxidative stress and inflammation markers of individuals with Temporomandibular Disorders (TMD) and healthy subjects.

Study design, setting, and sample: A prospective cross-sectional study was conducted. 27 TMD patients diagnosed with disc displacement (DD) according to RDC/TMD and 17 healthy subjects were enrolled in the study. Prior to any treatment, serum and saliva samples were taken from the patients and centrifuged, and stored at -80°C until analyzed. All samples were examined for IL-6, MDA and 8-OHdG concentrations.

Predictor variable: Diagnosis of disc displacement (RDC/TMD) Main outcome variables: Levels of 8-OHdG, IL-6 and MDA Covariates: Age and gender

Conditions

Interventions

OTHER

Biochemical analysis

Oxidative stress and inflammation markers were analyzed in serum and saliva of TMD and healthy subjects.

Sponsors & Collaborators

  • Bahçeşehir University

    lead OTHER

Principal Investigators

  • Dilara Kazan · Bahçeşehir University

Eligibility

Min Age
14 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-19
Primary Completion
2023-03-28
Completion
2023-04-19

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05985733 on ClinicalTrials.gov